Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced Q1FY26 results Revenue from Operations: Rs 551.7 crore compared to Rs 502.4 crore during Q1FY25, change 9.8%. EBITDA: Rs 69.5 crore compared to Rs 58.2 crore during Q1FY25, change 19.5%. EBITDA Margin: 12.4% for Q1FY26. PAT: Rs 34.0 crore compared to Rs 29.7 crore during Q1FY25, change 14.4%. PAT Margin: 6.1% for Q1FY26. Vikas Gupta, Joint Managing Director, said: “We are delighted to report an outstanding start to FY26, with Q1 results reflecting strong execution and strategic clarity. Despite challenging macroeconomic Conditions and pricing pressures, with several key product prices having bottomed out, IOL has delivered impressive performance, underscoring the resilience of our integrated business model. Our continued focus on portfolio diversification is yielding results, with non-Ibuprofen APIs gaining traction across global markets. With the commissioning of our fully backwardintegrated Paracetamol production unit, we are increasing our presence in both regulated and non-regulated markets. This positions us well to capture emerging opportunities, especially in regions where quality and compliance remain key differentiators. In the chemicals segment, the successful REACH registration of Acetic Anhydride under EU norms opens up new growth avenues in Europe, reinforcing our commitment to global standards and market expansion. As we move forward, our priorities remain clear — to scale high-value APIs, deepen our export footprint, and drive operational excellence. With a robust balance sheet and a strong innovation pipeline, we are confident in our ability to deliver sustainable growth and long-term value for all stakeholders.” Result PDF
Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations: Rs 527.8 crore (4.7% YoY growth) Gross Profit: Rs 186.5 crore (-1.3% YoY decline) Gross Margin: 35.0% (-190 bps YoY) EBITDA: Rs 67.5 crore (17.1% YoY growth) EBITDA Margin: 12.7% (+141 bps YoY) Profit After Tax (PAT): Rs 31.6 crore (12.2% YoY growth) PAT Margin: 5.9% (+43 bps YoY) Cash Profit After Tax: Rs 56.4 crore (14.6% YoY growth) FY25 Financial Highlights: Revenue from Operations: Rs 2,079.2 crore (compared to Rs 2,132.8 crore in FY24) Gross Profit: Rs 709.8 crore (compared to Rs 765.9 crore in FY24) Gross Margin: 33.8% (compared to 35.4% in FY24) EBITDA: Rs 224.6 crore (compared to Rs 261.6 crore in FY24) EBITDA Margin: 10.7% (compared to 12.1% in FY24) Profit After Tax (PAT): Rs 101.0 crore (compared to Rs 135.4 crore in FY24) PAT Margin: 4.8% (compared to 6.3% in FY24) Cash Profit After Tax: Rs 185.1 crore (compared to Rs 208.5 crore in FY24) Commenting on the performance, Vikas Gupta, Joint Managing Director said, “In Q4FY25, we delivered sustainable performance, with the Ibuprofen segment showing improved traction despite intense competition and continued pricing pressure in global markets. A key highlight was the successful commissioning of our fully backward-integrated Paracetamol production unit, with an installed capacity of 10,800 MTPA. This has tripled our Paracetamol capacity, enabling us to strengthen our non-Ibuprofen portfolio, particularly in high-demand, fast-moving therapeutic categories. Notably, pricing and demand across our broader API basket remained stable. However the chemicals segment delivered stable performance despite muted volumes, as enhanced operational efficiencies across key units contributed to a notable improvement in EBIT. FY25 was marked by strategic consolidation and investments focused on capacity enhancement, improved utilization, cost control, and regulatory expansion. Our strong backward integration model continues to drive cost control, supply reliability, and operating leverage. We remain committed to strengthening our portfolio, driving operational excellence, and expanding our market reach to create sustained value.” Result PDF
Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced Q3FY25 results Total Income: Rs 527.37 crore compared to Rs 528.77 crore during Q3FY24, change -0.26%. EBITDA: Rs 50.94 crore compared to Rs 52.86 crore during Q3FY24, change -3.63%. EBITDA margin: 9.66% for Q3FY25. PAT: Rs 20.55 crore compared to Rs 23.23 crore during Q3FY24, change 11.5%. PAT margin: 3.90% for Q3FY25. Vikas Gupta, Joint Managing Director, said: “We are pleased to report our Q3FY25 Results as despite challenges such as pricing pressures, stagnant demand, and intense market competition, the company has successfully maintained stable and sustainable performance. This resilience reflects our strategic approach and adaptability in a dynamic business environment. Confident of our resilient performance, the Board has declared an interim dividend of Rs 4/- (40%) per share of face value of Rs 10 each for FY25 and fixed a Record Date for 18th February 2025 for ascertaining the entitlement. Moving forward, we remain committed to our longterm vision by focusing on market diversification and expansion to unlock new growth opportunities. Additionally, we are implementing comprehensive cost optimization measures to enhance operational efficiency, improve profitability, and reinforce our competitive position. ” Result PDF
Conference Call with IOL Chemicals and Pharmaceuticals Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Total Income: Rs 532.18 crore compared to Rs 552.41 crore during Q2FY24, change -3.66% YoY. EBITDA: Rs 47.99 crore compared to Rs 71.21 during Q2FY24, change -32.61% YoY. EBITDA Margin: 9.02% for Q2FY25. PAT: Rs 19.15 crore compared to Rs 37.79 crore during Q2FY24, change -49.33 YoY. PAT Margin: 3.60% for Q2FY25. H1FY25 Financial Highlights: Total Income: Rs 1041.94 crore compared to Rs 1122.65 crore during H1FY24, change -7.19% YoY. EBITDA: Rs 106.17 crore compared to Rs 151.13 during H1FY24, change -29.75% YoY. EBITDA Margin: 10.19% for H1FY25. PAT: Rs 48.83 crore compared to Rs 84.00 crore during H1FY24, change -41.87%YoY. PAT Margin: 4.69% for H1FY25. Vikas Gupta, Joint Managing Director, said: "We are pleased to report sustainable revenue growth in Q2FY25, reflecting the resilience of our core business. However, we faced some margin pressure during the quarter, driven by challenges in selling price. To address this, we are taking proactive measures to optimize marketing strategies, cost structure and enhance operational efficiencies, with the goal of improving profitability in the coming periods. Despite these challenges, we remain confident in the long-term growth potential of the business." Result PDF
Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced Q1FY25 results: Total Income: Rs 509.8 crore (decreased by 0.3% QoQ, decreased by 10.6% YoY) EBITDA: Rs 58.2 crore (increased by 1.0% QoQ, decreased by 27.2% YoY) EBITDA Margin: 11.4% (increased by 10 basis points QoQ, decreased by 260 basis points YoY) PAT: Rs 29.7 crore (increased by 5.3% QoQ, decreased by 35.7% YoY) PAT Margin: 5.8% (increased by 30 basis points QoQ, decreased by 230 basis points YoY) Commenting on the performance, Vikas Gupta, Joint Managing Director said, “Despite facing challenging geopolitical conditions, the Company has successfully maintained operational performance, demonstrating resilience in absorbing the pricing volatility of raw materials for chemicals and intermediates. With the recent approvals from various regulatory authorities, we are excited to explore untapped opportunities in regulated markets. Our commitment to enhancing operational efficiency remains steadfast as we embrace cutting-edge technology, all while striving to minimize our carbon footprint. We are dedicated to driving sustainable growth and setting new benchmarks in our industry.” Result PDF